Fig. 2: Protein properties of Vav1 mutants. | Oncogenesis

Fig. 2: Protein properties of Vav1 mutants.

From: Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Fig. 2

a Expression of Vav1 in NIH3T3 cells stably transfected with pcDNA3, Vav1, and oncVav1 and the mutants E59K, D517E, and L801P was analyzed. Cells were treated with 25 μM of the proteasome inhibitor MG132 for 4 h or were left untreated. Cell lysates were immunoblotted with anti-Vav1 and anti-actin antibodies. b D517E is a highly stable protein. The half-life of Vav1 mutant proteins was measured by using CHX to block new protein synthesis. NIH3T3 cells stably expressing pcDNA3, Vav1, oncVav1, E59K, D517E, and L801P were treated with 100 μg/ml CHX for the indicated time periods. Cells were immunoblotted using anti-Vav1 and anti-actin antibodies. Results were quantified with the ImageJ program. c The histogram presents the mean time required for each protein to reach its half-life calculated by using Calculation was made for several time points. Error bars are indicated

Back to article page